Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial

References

• Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000;15:319–28
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445–52
   PubMed Web of Science ®Google Scholar
• Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003;8(Suppl 1):53–61
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005;10:49–56
   PubMed Web of Science ®Google Scholar
• Baldwin D.S, Huusom AKT, Mæhlum E. A randomized, placebo-controlled, double-blind study of escitalopram and paroxetine in the treatment of generalized anxiety disorder (GAD). Br J Psychiatry [Accepted 2006;189: 264–72]
   Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19:234–40
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161–7
   Google Scholar
• Gartlehner G, Hansen R, Kahwati L. Drug class review on second generation antidepressants. 2006. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm [last accessed December 2006]
   Google Scholar
• Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother 2006;4:201–9
   PubMedGoogle Scholar
• Blank S, Lenze EJ, Mulsant BH, et al. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry 2006;67:468–72
   PubMed Web of Science ®Google Scholar
• Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003;53:772–7
   Google Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006;9:495–505
   Google Scholar
• McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40–66
   Google Scholar
• Ware J.E. SF-36 physical and mental health summary scales: a user’s manual. Boston: The Health Institute, New England Medical Center; 1994
   Google Scholar
• Lerner D, Amick III BC, Rogers WH, et al. The Work Limitations questionnaire. Med Care 2001;39:72–85
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002,21: 271–92
   Google Scholar
• Perugi G, Frare F, Toni C, et al. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiology 2002;46:145–9
   PubMed Web of Science ®Google Scholar
• Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005;19:483–7
   PubMed Web of Science ®Google Scholar
• Lamers LM, Bouwmans CA, van Straten A, et al. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ 2006;15:1229–36
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873–84
   PubMed Web of Science ®Google Scholar
• Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 2005;14:1169–89
   PubMed Web of Science ®Google Scholar
• Pickard AS, Wang Z, Walton SM, Lee TA. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes 2005;3:11
   PubMedGoogle Scholar
• Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust New Zealand J Psychiatry 2004;38:602–12
   PubMed Web of Science ®Google Scholar
• Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med 2004;34:19–35
   PubMed Web of Science ®Google Scholar
• Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull WHOo 2000;78:?
   Google Scholar
• Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years to assess the global burden of disease. Bull WHOo 1994;72:429–45
   PubMed Web of Science ®Google Scholar
• Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006;21:402–8 [epub 2006 July 28]
   Google Scholar
• Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care 2007;13:211–7 [review]
   Google Scholar